Renovar, Inc. is a bioscience company that has developed novel urine-based in vitro diagnostic assays to predict various kidney diseases. The company's non-invasive technology is based on the identification of key bio-markers found in urine that will enable physicians to predict ensuing kidney disease far in advance of existing diagnostics with far greater sensitivity and specificity. NEW Capital Fund licensed this technology to ThermoFisher Scientific in 2018.
Portfolio Companies
Niche and Advanced Manufacturing
Information Technology
Life and Material Sciences
Life and Material Sciences
Biotech and medical device companies with novel intellectual property and applied materials businesses whose products offer economic value that is easy to quantify
Renovar, Inc
Portfolio Companies
We focus on making early stage life and material science, information technology and growth stage niche and advanced manufacturing investments.